Progesterone, which belongs to the group of sex steroid hormones, is suggested to play an important role in many kinds of diseases. RU486, the only clinically available progesterone antagonist, has been reported to have a potential therapeutic effect in the treatment of breast cancer1}, endometriosis2), uterine leiomyomata2) and meningioma3 '4) , according to initial results from clinical trials. In addition, recent studies suggest that progesterone may promote bone formation in ovariectomized rats5) and protect against bone loss in breast-feeding women6). Thus, agonists of progesterone could serve in the treatment of established osteoporosis. However, present clinically available progesterone agonists and antagonists all possess the steroidal moiety which results in the appearance of the side effects associated with the administration of steroids. This is especially the case for steroidal progesterone antagonists which are not suitable for long-term treatment because of their potent antiglucocorticoid activity in humans. For example, side effects thought to be caused by antiglucocorticoid activity were reported in some clinical trials of RU4861>4). For these reason, it seems imperative that new agonists and antagonists of progesterone be isolated that lack the steroid moiety.
In the course of screening for progesterone receptor ligands, we discovered the presence of three nonsteroidal and functional ligands, namely PF1092A, B and C, in the extracts of cell cultures of Penicillium oblatum. In this paper, we describe the taxonomy and fer- APR. 1997 mentation of strain PF1092, and the isolation and biological activities of these new progesterone receptor ligands ( Fig. 1) . The physico-chemical properties, structure elucidation and total synthesis of PF1092A, B and C will be described in the following papers7'8).
Materials and Methods

Taxonomic Studies
The fungal strain PF1092 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan, under the accession number FERMP-14724. Taxonomic studies of the strain PF1092 were done according to the method of Pitt9). The color guide of Kornerup and Wanscher10) wheat germ, 0.2% soybean meal, 0.3% yeast extract, 0.5% Polypepton (Nihon Pharmaceutical Co., Ltd.), 0.2% CaCO3and tap water (pH 7.0 before sterilization).
The inoculated flask was shaken on a rotary shaker (200rpm) at 25°C for 3 days. One milliliter of the first seed culture was transferred into 100 ml of the same medium in 500-ml Erlenmeyer flasks. After shaking at 25°C for 3 days, five milliliters of the second seed culture was added to a 500-ml Erlenmeyer flasks containing 100 g of production mediummadeup of rice containing water and 2.5% soybean meal (pH non-adjusted). The inoculated flasks were incubated as stationary phase cultures for 17 days at 28°C. The progress of fermentation was monitored by high performance liquid chromatography (HPLC). The rice media sampled atday 7, 10, 12, 14, and 17 were extracted with twice their weight of 67% aq. acetone. The extract was filtered and the filtrate was injected into the injector of a Shimadzu LC-6AD HPLC. Capcell pak C18 (Shiseido Co., Ltd.) column was used at a flow rate of 0.8 ml/minute. The mobile phase was an aqueous solution of 50% acetonitrile. PF1092s were monitored with UV detector (Shimadzu SPD-6AV) at 320 nm. The retention time ofPF1092A, B and C were 3.9 minutes, 4.9 minutes and 3.3 minutes, respectively.
Progesterone Binding Assay (a) Receptor Preparation Unless specified, the following procedures were carried out at 0~4°C. The uteri of porcine were homogenized in buffer consisting of 5mMKH2PO4 (pH 7.4), 30% glycerol, 0.1% a-thioglycerol and 25/xg/ml leupeptin and the homogenates were then sonicated with a Branson Sonifier 450 on ice followed by centrifugation at 100,000 x g for 30 minutes. The resulting supernatant (cytosol) was stored at -80°C until use and used as a source of progesterone receptors for the binding assays.
(b) [3H]-Progesterone Binding Assay
The reaction mixture (100jA) containing 50mM KH2PO4 (pH 7.4), 10% glycerol, 0.1% a-thioglycerol, 25^g/ml leupeptin, 1 mMEDTA and [1,2,6,7-3H(N) ] progesterone (final concentration of 2.0nM at 6.8 kBq/ ml-New England Nuclear, specific activity 3.4TBq/ mmol), porcine uteri cytosol preparation (l~2mg protein/ml) and a test sample were incubated for 1 hour at 4°C. After incubation, 100jA of dextran coated charcoal solution consisting of 0.5% Norit A (Nacalai Tesque, Inc., Kyoto, Japan ) and 0.05% Dextran T-70
(Pharmacia Fine Chemicals, Ltd., Uppsala, Sweden) were added to the incubation mixture and further 305 incubated at 4°C for 10 minutes. The mixture was then centrifuged at 1800 rpm for 5 minutes. The radioactivity of lOO/il of the supernatant was counted in 2ml of Aquasol-2 (Packard Instrument B.V. Chemical Operations, Groningen, Netherlands ) with a liquid scintillation counter (Beckman LS6500). Non specific binding was defined as the binding observed when lO^g/ml of cold progesterone was added to the reaction mixture.
Results
Taxonomy of Strain PF1092
The mycological characteristics of strain PF1092 were as follows. Colonies growing on CYAat 25°C attained a diameter of 20~25mmin 7 days, and were white, floccose, and slightly funiculose. Conidiogenesis was sparse but was produced in sufficient quantities to influence colony appearance within 7 days. Exudate and soluble pigment were absent. The reverse sides of the colonies were Chamois (4C5). Colonies growing on MEA at 25°C attained a diameter of30~40mmin 7 days, and were white, floccose, and slightly funiculose. Conidiogenesis was sparse. Apale brown exudate were produced. The reverse side of the colonies were Light Brown(5D5). At 37°C the growth-rate was increased and conidiogenesis was abundantly produced.
Penicilli were monoverticillate. Stipes ofconidiophores were verrucose walled, 30~70 x 2.5~3.5/mi. Phialides were acerose, smooth to slightly roughened, 4~7 per stipe, 8~10 x 2.5~3 /mi. Conidia were globose to oblate, smooth-walled, 2~2.5 /mi, borne in short columns (Fig.   2 ). Based on the properties listed above, strain PF1092 was identified as Penicillium oblatum Pitt et Hocking1 1}.
Production of PF1092s A typical time course of the fermentation of PF1092A, B and C are shown in Fig. 3 . The production ofPF1092A, B and C reached a maximumafter 14 days offermentation and the yields were 39 jUg/ml, 1 1 jug/ml and 38 jUg/ml, respectively.
The inhibitory effect on the [3H]-progesterone binding assay (final broth extract concentration of 0.3% in the assay) reached a level of 91% inhibition after 14 days of fermentation (data not shown).
Isolation
The isolation scheme is shown in Fig. 4 . The fermented rice medium (6 kg (2 : 1 -1 : 1)) was evaporated to give apale yellowpowder containing PF1092A and PF1092C (763mg). The pale yellow powder containing PF1092B was applied to a column of Sephadex LH-20 (700ml). The column was eluted with MeOHand the eluted fraction was evaporated to give a colorless powder of PF1092B (157mg). The colorless powder was dissolved in CHC13-MeOH and crystallized to give colorless needles of PF1092B (49mg). The pale yellow powder containing PF1092A and PF1092Cwas applied to a column of Sephadex LH-20 (700ml). The column was eluted with MeOHand the eluted fractions was evaporated to give a colorless powder of PF1092A (298mg) and PF1092C (159mg). The colorless powder was dissolved in CHC13-MeOH and crystallized to give colorless needles of PF1092A (60mg) and PF1092C (30mg).
Biological Activities PF1092A, B and C inhibited
[3H]-progesterone binding to the progesterone receptor isolated from porcine uteri in a dose dependent manner (Fig. 5) . The concentrations required for IC50 were 3.0x l0nM for Neither PF1092A, B or C showed cytotoxcity in vitro against HMV-1 (melanoma, human), KB (epidermoid carcinoma, human), MKN-1(stomach cancer, human), human) , and T24 cells (bladder carcinoma, human) at the concentration of 10 aglml.
Discussion
Progesterone plays important roles not only in the reproductive organs but also in bone and the central nerve system (CNS)12).
Pharmaceutical studies of progesterone antagonists have been performed using progesterone agonists could be potentially efficacious for the treatment of established osteoporosis5 '6) . All of the progesterone agonists or antagonists currently available or in clinical development are derived from steroids and consequently, many of them show cross-activity with other steroid receptors. The major aim of our research has been to find highly selective progesterone agonists or antagonists free from steroidal side-effects.
Recently, some nonsteroidal progesterone receptor ligands have been synthesized from cyclocymopol monomethyl ether derived from the natural products, cymopol13'14) and 3-aryl-l-benzoyl-l,4,5,6-tetrahydropyridazines15'16 Therefore, PF1092A or its derivatives may modulate positively or negatively the progesterone receptor without modulating other steroidal hormone receptors. We envisage that PF 1092s could be optimized for therapeutic use as an agonist or an antagonist.
